Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
cancer
7
×
life sciences
national blog main
san francisco blog main
7
×
biotech
boston top stories
national top stories
san francisco top stories
clinical trials
cancer drugs
europe blog main
ipo
europe top stories
fda
indiana blog main
indiana top stories
new york blog main
new york top stories
novartis
sanofi
startups
venture capital
biogen
blueprint medicines
boulder/denver blog main
boulder/denver top stories
deals
deerfield management
detroit blog main
detroit top stories
eli lilly
general atlantic
gilead sciences
melinta therapeutics
national
non-small cell lung cancer
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
What
medicines
7
×
cancer
ipo
drug
new
research
bio
covid
fda
proteins
revolution
roundup
targeted
targets
acquisitions
activity
address
aim
announced
approval
approvals
approves
biogen
biotech
black
blueprint
boost
cancer’s
carries
ceo
certain
change
clamped
clinic
collabs
community
companies
daniel
deal
delays
Language
unset
Current search:
medicines
×
cancer
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care